title: Important Factors Affecting Adjuvant Treatment Decision in Stage IA Breast Cancer Patients in Turkey.
abstract: BACKGROUND
  In Turkey, the gene expression profile test is not standard, so adjuvant treatment is planned according to clinicopathological factors. Therefore, we retrospectively analyzed important parameters that affect the decision on adjuvant chemotherapy, and also factors related to survival in stage IA breast cancer patients in Turkey.
  
  
  METHODS
  We retrospectively evaluated 347 stage IA patients. The relationship between the clinicopathological parameters and adjuvant chemotherapy was analyzed.
  
  
  RESULTS
  The median age and follow-up time were 52 years (range: 25-86) and 22.6 months (range: 1-113), respectively. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 87.9% and 98.7%, respectively, but the median DFS was not reached. Age, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and the presence of triple-negative breast tumor (TNBC) were related to DFS, and lymphovascular invasion (LVI), perineural invasion (PNI), HER2 status, the presence of TNBC, and recurrence were related to OS (p > 0.05). Furthermore, age, menopausal status, multicentricity, grade, tumor size, necrosis, ER, the presence of TNBC, and HER2 were found to be related to adjuvant therapy decision (p > 0.05). All these parameters, in addition to LVI and PNI, were independent factors for chemotherapy by logistic regression analysis.
  
  
  CONCLUSIONS
  In decisions about adjuvant therapy in stage IA breast cancer patients, clinicopathological factors should be kept in mind.
authors.affiliation: Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
authors.forename: Bala B
authors.initials: BB
authors.lastname: Oven Ustaalioglu
authors.affiliation: Department of Medical Oncology, Medipol University, Istanbul, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.affiliation: Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
authors.forename: Burçak E
authors.initials: BE
authors.lastname: Yilmaz
authors.affiliation: Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Aliustaoglu
authors.affiliation: Department of Medical Oncology, Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.affiliation: Department of Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
authors.forename: Fugen
authors.initials: F
authors.lastname: Vardar
authors.affiliation: Department of Medical Oncology, Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
keywords: Adjuvant therapy; Breast cancer; Chemotherapy; Stage IA